Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle

FEBS Letters
K E WellsD J Wells

Abstract

Long-term high-level in vivo gene expression appears to depend on the promoter chosen to drive the gene of choice. In many cases the promoter appears to 'switch off' some time after in vivo gene transfer. We demonstrate that, following intramuscular injection of beta-galactosidase reporter plasmids, promoter 'switch off' is due to elimination of fibres expressing the transferred reporter gene by activation of a Th1 (cytotoxic) immune response. This finding, in the absence of stimulation of the immune system by viral vector proteins, has implications not only for gene transfer experiments but for the future of muscle-directed gene therapy.

References

Sep 1, 1992·Human Molecular Genetics·J A WolffA Jani
Feb 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N E Street, T R Mosmann
Sep 14, 1990·Journal of Immunological Methods·Y Aida, M J Pabst
Feb 1, 1985·Molecular and Cellular Biology·P A Norton, J M Coffin
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·E RazM A Yankauckas
Jan 1, 1994·Human Gene Therapy·M VitadelloS Schiaffino
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·E RazD A Carson

❮ Previous
Next ❯

Citations

Jul 18, 2001·Veterinary Immunology and Immunopathology·P H Russell, A Mackie
Mar 6, 1999·Vaccine·T KanellosP H Russell
Aug 5, 1998·Current Opinion in Genetics & Development·D J Marshall, J M Leiden
Jun 6, 2003·Best Practice & Research. Clinical Endocrinology & Metabolism·Geoffrey Goldspink
Jul 28, 2001·European Journal of Clinical Investigation·T T RissanenS Ylä-Herttuala
May 8, 1999·Immunology·T KanellosP H Russell
Sep 28, 1999·Clinical and Experimental Pharmacology & Physiology·M Y AlexanderH M Prentice
Aug 16, 2006·Neuro-degenerative Diseases·Francisco J Miana-MenaRosario Osta
Oct 10, 2014·Journal of Thrombosis and Haemostasis : JTH·M E FominM O Muench
Aug 31, 2006·Expert Opinion on Emerging Drugs·Matthieu D Lavigne, Dariusz C Górecki
Oct 30, 2007·BMC Biotechnology·Camille Allera-MoreauAnne-Catherine Prats
Jun 25, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Matthieu D LavigneDariusz C Górecki
Aug 9, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·F GinhouxH Firat
Nov 10, 2006·Journal of Biomechanics·Scott C Bryer, Timothy J Koh
Sep 26, 2001·Gene Therapy·G MacCollD C Górecki
Jun 17, 1998·Developmental Dynamics : an Official Publication of the American Association of Anatomists·K Wertz, E M Füchtbauer
Jun 6, 2000·American Journal of Physiology. Cell Physiology·P L HallauerK E Hastings
Jun 11, 1998·Journal of Pharmaceutical Sciences·D J WellsK E Wells
Feb 3, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Chien-Wen ChangSung Wan Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.